MB
AVDL

MPM BioImpact’s Avadel Pharmaceuticals AVDL Stock Holding History

MPM BioImpact’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-783,242
Closed -$11M – 46
2024
Q2 		$11M Sell
783,242
-87,907
-10% -$1.43M 1.71% 20
2024
Q1 		$14.7M Buy
871,149
+206,163
+31% +$3.07M 2.37% 13
2023
Q4 		$9.39M Buy
664,986
+762
+0.1% +$8.95K 2.2% 18
2023
Q3 		$6.84M Buy
664,224
+279,234
+73% +$3.74M 1.83% 20
2023
Q2 		$6.34M Buy
+384,990
New +$5M 1.28% 25
2022
Q4 		– Sell
-412,363
Closed -$2.07M – 35
2022
Q3 		$2.07M Hold
412,363
– – 0.49% 31
2022
Q2 		$1.01M Hold
412,363
– – 0.28% 35
2022
Q1 		$2.82M Buy
412,363
+37,037
+10% +$255K 0.76% 31
2021
Q4 		$3.03M Sell
375,326
-24,674
-6% -$226K 0.55% 29
2021
Q3 		$3.92M Buy
+400,000
New +$3.15M 0.61% 30

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

MPM BioImpact's AVDL Position: Q3 2024 in Review

MPM BioImpact sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 783,242 shares — an estimated $11M sold.

MPM BioImpact first reported a position in AVDL in Q3 2021 and held it in 10 quarters. The position peaked at $14.7M in Q1 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • MPM BioImpact reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • MPM BioImpact sold 783,242 Avadel Pharmaceuticals shares in Q3 2024, an estimated $11M.
  • MPM BioImpact first reported a position in Avadel Pharmaceuticals in Q3 2021 and held it in 10 quarters.
  • MPM BioImpact's Avadel Pharmaceuticals position peaked at $14.7M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.